Oppenheimer Believes Omnicell (NASDAQ: OMCL) Still Has Room to Grow
In a report released today, Mohan Naidu from Oppenheimer reiterated a Buy rating on Omnicell (NASDAQ: OMCL), with a price target of $55. The company’s shares closed yesterday at $52.55, close to More »
Analysts Offer Insights on Healthcare Companies: Allergan (NYSE: AGN) and Abbott Labs (NYSE: ABT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allergan (NYSE: AGN) and Abbott Labs (NYSE: ABT) with bullish sentiments. Allergan (NYSE: AGN) More »
